HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

SB 204269

structure in first source

Also Known As:

SB-204269

Networked: 3 relevant articles (1 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Related Diseases

1.	Epilepsy (Aura) 10/31/1996 - "The excellent anticonvulsant profile of SB 204269, combined with the identification of a unique binding site for the compound, suggest that it has potential clinical utility as a novel treatment for epilepsy." 09/01/1998 - "SB-204269 is an anticonvulsant agent under development by SmithKline Beecham, It is in phase II clinical trials as a potential treatment for epilepsy [243338]. "
2.	Seizures (Absence Seizure) 08/01/1997 - "9. The overall efficacy profile in rodent seizure models, together with a minimal liability for inducing neurological impairment and an apparently unique mechanism of action, highlight the therapeutic potential of SB-204269 for the treatment of refractory partial and generalized tonic-clonic seizures." 08/01/1997 - "Profile of SB-204269, a mechanistically novel anticonvulsant drug, in rat models of focal and generalized epileptic seizures." 08/01/1997 - "3. SB-204269 proved to be an orally-effective anticonvulsant agent, at doses (0.1-30 mg Kg-1) devoid of overt behavioural depressant properties, in models of both electrically (MEST and maximal electroshock (MEST)) and chemically (i.v. pentylenetetrazol (PTZ) infusion)-evoked tonic extension seizures. "
3.	Ataxia (Dyssynergia) 08/01/1997 - "7. In the rat accelerating rotarod test, a sensitive paradigm for the detection of neurological deficits such as sedation and motor incoordination, SB-204269 was inactive even at doses as high as 200 mg kg-1, p.o. "

Related Drugs and Biologics

1.	Anticonvulsants (Antiepileptic Drugs)
2.	Pentylenetetrazole (Metrazol)